

May 19, 2017

The Bombay Stock Exchange of India Ltd.  
1<sup>st</sup> Floor, Rotunda Building, Dalal Street,  
Fort- Mumbai 400001

Dear Sir/Madam,

**Sub:** Re-filing of quarterly financial results in the revised format

Dear Sir,

Reference your email dated May 17, 2017 stating that the 1<sup>st</sup> quarter financial results as filed by the Company are not in the format.

We are enclosing herewith the same results in the revised format as per Schedule III of the Companies Act 2013.

Trust you will find the same in order.

**Yours faithfully,  
For Merck Limited**



**N. Krishnan  
CFO & Executive Director (Finance)**

Encl : As above



**Merck Limited**

Registered Office  
Godrej One, 8<sup>th</sup> Floor, Pirojshanagar  
Eastern Express Highway, Vikhroli East  
Mumbai 400079, India.  
Phone +91 22 62109000  
Fax +91 22 62109999  
www.merck.co.in  
CIN: L99999MH1967PLC013726

**MERCK LIMITED**

Regd. Office: Godrej One, 8th Floor, Eastern Express Highway, Pirojshanagar, Vikhroli (East), Mumbai : 400 079.  
CIN No. L99999MH1967PLC013726, email : corpsec@merckgroup.com

**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST MARCH, 2017**

				(Rs in lakhs)						(Rs in lakhs)	
	Particulars	3 months ended	3 months ended	Sr. No.	Particulars	3 months ended	3 months ended			3 months ended	3 months ended
		31/03/2017	31/03/2016			31/03/2017	31/03/2016				
		Unaudited	Unaudited								
1.	<b>Revenue from Operations</b>			1.	<b>Segment Revenue</b>						
	Sales	22,987.69	21,028.55		a) Pharmaceuticals	18,814.53	16,921.35				
	Other operating income	704.51	525.71		b) Chemicals	4,877.67	4,832.91				
2.	<b>Other Income</b>	667.51	541.30		Total	23,692.20	21,554.26				
3.	<b>Total income (1+2)</b>	24,359.71	22,095.56		Less : Inter segment revenue	-	-				
4.	<b>Expenses</b>				Revenue from operations (net)	23,692.20	21,554.26				
	a) Cost of materials consumed	5,598.20	6,396.80	2.	<b>Segment Results (Profit before Tax and Interest from each segment)</b>						
	b) Purchases of stock-in-trade	4,097.26	2,192.38		a) Pharmaceuticals	2,025.80	358.15				
	c) Changes in inventories of finished goods,work-in-progress and stock in trade	(479.15)	(67.19)		b) Chemicals	(236.90)	104.40				
	d) Excise duty	42.61	124.85		Total	1,788.90	462.55				
	e) Employee benefits expense	4,096.41	3,505.93		Less :						
	f) Finance Costs	0.85	1.12		Other un-allocable expenditure net off un-allocable income	(517.25)	(588.71)				
	g) Depreciation and amortisation expense	623.40	625.08		Total Profit before Tax	2,306.15	1,051.26				
	h) Other expenses	8,073.98	8,265.33	3.	<b>Capital Employed</b>						
	<b>Total expenses (4)</b>	22,053.56	21,044.30		<b>Segment Assets</b>						
5.	<b>Profit before exceptional items and tax (3-4)</b>	2,306.15	1,051.26		Pharmaceuticals	35,290.21	29,570.92				
6.	Exceptional items	-	-		Chemicals	13,912.02	18,186.33				
7.	<b>Profit before tax</b>	2,306.15	1,051.26		Unallocated	41,811.71	31,180.40				
8.	<b>Tax Expenses</b>				<b>Total Assets</b>	91,013.94	78,937.65				
	Current Tax	1,062.00	700.00		<b>Segment Liabilities</b>						
	Deferred Tax	(238.55)	(488.85)		Pharmaceuticals	16,835.48	14,086.94				
9.	<b>Profit for the period (7-8)</b>	1,482.70	840.11		Chemicals	4,502.70	2,514.20				
10.	<b>Other Comprehensive Income</b>				Unallocated	1,428.95	647.98				
	Items that will not be reclassified to profit or loss				<b>Total Liabilities</b>	22,767.13	17,249.12				
	i. Re-measurement (losses) on defined benefit plans	(56.10)	(22.25)		<b>Capital Employed</b>						
	ii. Income tax relating to items that will not be reclassified to profit or loss	19.42	7.70		Pharmaceuticals	18,454.73	15,483.98				
	<b>Total Other Comprehensive Income</b>	(36.68)	(14.55)		Chemicals	9,409.32	15,672.13				
11.	<b>Total Comprehensive Income for the period (9+10)</b>	1,446.02	825.56		Unallocated	40,382.76	30,532.42				
12.	Paid-up equity share capital (Face Value Rs 10/- each)	1,659.94	1,659.94		<b>Total</b>	68,246.81	61,688.53				
13.	<b>Earnings per equity share ( of Rs 10/- each) (not annualised):</b>										
	(a) Basic	8.93	5.06								
	(b) Diluted	8.93	5.06								

**Notes:**

- The above results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at its meeting held on 03 May 2017. These results have been subjected to "Limited Review" by the statutory auditors of the company. The review report has been filed with stock exchange and is available on the company's website.
- The Company adopted Indian Accounting Standards ("Ind AS") from 01 January 2017 and accordingly these results have been prepared in accordance with recognition and measurement principles laid down in Ind AS 34, Interim Financial Reporting prescribed under section 133 of Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India. Financial results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS 34. The figures of the quarter ended 31 March 2016 have not been subject to limited review or audit. However, the management has exercised necessary due diligence to ensure that the financial results provide true and fair view of the Company's affairs.
- Reconciliation of Net Profit as previously reported on account of transition from the previous GAAP to Ind-AS for the quarter ended 31 March 2016

Sr No	Particulars	Rs. in lakhs
		Unaudited
	Net Profit for the period under previous GAAP	1,224.58
a.	Additional provision for doubtful debts based on expected credit loss method under Ind AS 109	(83.84)
b.	Revenue recognition - measurement of revenue	(525.24)
c.	Charge of imputed interest on security deposit	(1.13)
d.	Deferred tax on above adjustments	211.17
	<b>Net Profit for the period under Ind AS</b>	<b>825.56</b>

- Figures for the previous quarter/year have been re-grouped/re-arranged wherever necessary.
- These quarterly results for the period ended March 31, 2017, are being re-filed in revised format, in view of the communication received from stock exchanges. Originally these accounts were filed on May 03, 2017. All other facts and figures as shown earlier has remained unchanged.

For and on behalf of MERCK LIMITED

  
N. Krishnan  
Executive Director



# B S R & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,  
Apollo Mills Compound  
N. M. Joshi Marg, Mahalaxmi  
Mumbai - 400 011  
India

Telephone +91 (22) 4345 5300  
Fax +91 (22) 4345 5399

## Limited Review Report on Quarterly Financial Results of Merck Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of Merck Limited

We have reviewed the accompanying statement of unaudited financial results ('the Statement') of Merck Limited ('the Company') for the quarter ended 31 March 2017 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Attention is drawn to the fact that the figures for the corresponding quarter ended 31 March 2016 including the reconciliation of net profit under Ind AS of the corresponding quarter with net profit for the quarter reported under previous GAAP, as reported in these financial results have been approved by the Company's Board of Directors but have not been subjected to review.


This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors in their meeting held on 3 May 2017. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of the Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated 5 July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**  
Chartered Accountants

Firm's Registration No: 101248W/W-100022



**Vikas R Kasat**  
Partner

Membership No: 105317

Mumbai  
03 May 2017